U.S., April 7 -- ClinicalTrials.gov registry received information related to the study (NCT07512050) titled 'Oral Lactobacillus Reuteri for Skin Barrier Dysfunction in Obesity' on Dec. 03, 2025.
Brief Summary: This clinical trial aims to evaluate the safety and efficacy of oral Lactobacillus reuteri supplementation for treating obesity-induced skin barrier impairment in individuals aged 18-40 with a BMI >=30. The study focuses on the following questions:
Can oral Lactobacillus reuteri supplementation reduce skin barrier damage (measured by transepidermal water loss/TEWL) in obese participants? Does modulation of gut microbiota with Lactobacillus reuteri impact skin barrier function and systemic inflammation?
Researchers will compare outc...